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ABSTRACT
The complexity of determining the variability in tacrolimus pharmacokinetics 
parameter among organ transplant patients and its narrow therapeutic window 
characteristics necessitates proper drug monitoring in order to ensure the level is 
maintained within therapeutic range. Many studies have reported that variability of 
tacrolimus pharmacokinetics was due to differential expression of drug metabolizing 
enzymes CYP3A4 and CYP3A5 encoded by CYP3A4 and CYP3A5 genes 
respectively. The aim of the study was to develop a genotyping method in detecting 
CYP3A4*18, CYP3A5*3 and CYP3A5*6 mutations as well as investigating any 
correlation of genotyping findings with the clinical and tacrolimus related 
pharmacokinetics data and to quantify enzyme expression through the relationship of 
CYP3A4 and CYP3A5 mRNA copy number with the patients’ genotypes. Five ml of 
blood were withdrawn from the 80 patients and the DNA was extracted, thus 
proceeded for genotyping of CYP3A4*18, CYP3A5*3 and CYP3A5*6 variants using 
two steps PCR technique. Absolute quantification was employed where the serial 
dilution of plasmid from cloned bacteria to generate a standard curve was done prior 
to real time PCR method. Nine of 80 patients were found to be heterozygous of 
CYP3A4*18 (11.25%). As result of CYP3A5*3 polymorphism, eight patients were 
found as homozygous wild type (10%), 31 patients were heterozygous (38.75%) and 
41 patients were homozygous mutant (51.25%). No CYP3A5*6 mutation was 
observed in this study. Homozygous mutant was significantly associated with lowest 
requirement of tacrolimus dose and highest adjusted level per dose (P<0.01). There 
was no significant correlation between CYP3A4 and CYP3A5 mRNA copy number 
with the CYP3A4*18 and CYP3A5*3 genotypes respectively. Significant correlation 
between CYP3A5*3 genotypes with the doses has provided a reliable information in 
predicting the appropriate individual tacrolimus doses.
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